American Century Companies Inc. Grows Position in Hologic, Inc. $HOLX

American Century Companies Inc. grew its position in Hologic, Inc. (NASDAQ:HOLX) by 23.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,651,994 shares of the medical equipment provider’s stock after acquiring an additional 312,011 shares during the quarter. American Century Companies Inc. owned 0.74% of Hologic worth $107,644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. United Services Automobile Association purchased a new position in shares of Hologic in the 1st quarter worth $347,000. K.J. Harrison & Partners Inc purchased a new stake in shares of Hologic during the 2nd quarter valued at about $1,987,000. Aberdeen Group plc lifted its holdings in shares of Hologic by 2.8% in the 2nd quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock valued at $15,964,000 after acquiring an additional 6,589 shares during the last quarter. Nordea Investment Management AB grew its position in Hologic by 7.2% in the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock worth $168,674,000 after acquiring an additional 174,828 shares in the last quarter. Finally, Carnegie Investment Counsel grew its position in Hologic by 10.6% in the second quarter. Carnegie Investment Counsel now owns 221,528 shares of the medical equipment provider’s stock worth $14,435,000 after acquiring an additional 21,273 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Up 0.2%

Shares of NASDAQ HOLX opened at $74.88 on Wednesday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $80.31. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company has a market cap of $16.69 billion, a price-to-earnings ratio of 31.07, a PEG ratio of 2.54 and a beta of 0.65. The business’s 50 day moving average price is $71.04 and its 200-day moving average price is $66.73.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter in the previous year, the business earned $1.01 EPS. Hologic’s revenue was up 6.2% compared to the same quarter last year. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Stephens downgraded Hologic from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $78.00 to $76.00 in a research report on Wednesday, October 22nd. UBS Group boosted their target price on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research report on Thursday, July 31st. BNP Paribas Exane lowered Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price target on the stock. in a report on Friday, November 21st. Raymond James Financial lowered shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Finally, Argus boosted their price objective on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Five equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus target price of $79.67.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.